Staphylococcus aureus in lower respiratory infections: Clinical relevance of antimicrobial resistance

Seminars in Respiratory Infections

Volumn 16, Issue 3, 2001, Pages 196-202

  Shah, Pramod M ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; LINEZOLID; METICILLIN; MOXIFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; PENICILLIN G; PIPERACILLIN; RIFAMPICIN; SULBACTAM; TAZOBACTAM; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; HOSPITAL INFECTION; INTENSIVE CARE UNIT; LOWER RESPIRATORY TRACT INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRAIN DIFFERENCE;

COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; HUMANS; LUNG DISEASES; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 0034832446     PISSN: 08820546     EISSN: None     Source Type: Journal    
DOI: 10.1053/srin.2001.25625     Document Type: Review

References (53)

1. Community-acquired pneumonia in adults: Guidelines for management
2. Community-acquired pneumonia
3. Community-acquired pneumonia
4. Pneumonia in the elderly
5. Community-acquired Staphylococcus aureus bacteraemia in patients who do not abuse intravenous drugs
6. Lower respiratory tract infections following cardiac arrest and cardiopulmonary resuscitation
7. Antimicrobial resistance among pneumonia isolates in Europe
8. The prevalence of nosocomial infection in intensive care units in Europe - Results of the European prevalence on infection in intensive care (EPIC) study
9. Methicillin-resistant Staphylococcus aureus: Acquisition and risk of death in patients in the intensive care unit
10. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms
11. Antimicrobial resistance of Staphylococcus aureus: Genetic basis
12. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: Therapeutic realities and possibilities
13. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota. 1997-1999
14. Community strain of methicillin-resistant Staphylococcus aureus involved in a hospital outbreak
15. The prevalence of nosocomial infection in intensive care units in Europe: Results of the European prevalence on infection in intensive care (EPIC) study
16. National Nosocomial Infection Surveillance System report: Data summary from October 1986-April 1996
17. Susceptibility of respiratory strains of Staphylococcus aureus to fifteen antibiotics: Results of a collaborative surveillance study (1992-1993)
18. Cryptic vancomycin-resistant Staphylococci (CV-RS) as a cause of treatment failure in Staphylococcus aureus (S.a.) bacteremia
19. Methicillin-resistant Staphylococcus aureus clinical strains with reduced vancomycin susceptibility
20. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu 50
21. Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany
22. Emergence of heterogenous intermediate vancomycin resistance in Staphylococcus aureus isolates in the DÅsseldorf area
23. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin
24. Emergence of vancomycin resistance in Staphylococcus aureus
25. New resistance in Staphylococcus aureus
26. Expression and detection of hetero-vancomycin resistance in Staphylococcus aureus
27. In vitro activity of bay 12-8039, a new 8-methoxyquinolone
28. Inhibition of protein synthesis by streptogramins and related antibiotics
29. Primary staphylococcal pneumonia in childhood: A review of 69 cases
30. The incidence and significance of Staphylococcus aureus in respiratory cultures from patients infected with the human immunodeficiency virus
31. Community-acquired pneumonia: Impact of immune status
32. Treatment of community-acquired pneumonia: A randomized comparison of sparfloxacin, amoxicillin-clavulanic acid and erythromycin
33. The economic impact of Staphylococcus aureus infection in New York City hospitals
34. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia
35. Influence of antimicrobial treatment on mortality in septicemia
36. Inadequate antimicrobial treatment of infections - A risk factor for hospital mortality among critically ill patients
37. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus
38. The use of rifampicin in staphylococcal infections - A review
39. Rifampicin in the treatment of osteoarticular infections due to staphylococci
40. Clinical study of combination therapy with oxacillin and rifampicin for staphylococcal infections
41. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin
42. Retrospective study of outcome in patients treated for Staphylococcus aureus bacteremia
43. Antimicrobial activity of fusidic acid and disk diffusion susceptibility testing criteria for gram-positive cocci
44. In-vitro antibacterial activity of fusidic acid alone and in combination with other antibiotics against methicillin-sensitive and -resistant Staphylococcus aureus
45. Alternatives to vancomycin in treating methicillin-resistant Staphylococcus aureus infections
46. Trimethoprimsulfamethoxazole compared with vancomycin for the treatment of staphylococcus aureus infection
47. Six years' experience in the global quinupristin/dalfopristin compassionate-use programme for treatment of gram-positive infections
48. In vitro evaluation of BO-3482, a novel dithiocarbamate carbapenem with activity against methicillin-resistant staphylococci
49. Comparative in-vitro activity of SCH 27899, a novel everninomicin, and vancomycin
50. In-vitro activity of DU-6859a against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibilities to vancomycin
51. Intracellular activity of vancomycin and Ly333328, a new semisynthetic glycopeptide, against methicillin-resistant Staphylococcus aureus
52. In vitro antibacterial activity of LY333328kl a new semisynthetic glycopeptide
53. Linezolid: Erste klinische erfahrungen in oxazolidinone-eine neue klasse von antibiotika